7Baggers

Tarsus Pharmaceuticals Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Net Income  
20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20240630 20240930 20241231 20250331 20250630 -41.9-35.92-29.93-23.94-17.96-11.97-5.990Milllion

Tarsus Pharmaceuticals Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 
                      
  revenues:                    
  product sales102,660,000 78,335,000 66,408,000 48,118,000 40,813,000 24,720,000 13,076,000 1,653,000             
  license fees and collaboration revenue     2,894,000  218,000  2,500,000           
  total revenues102,660,000 78,335,000 66,408,000 48,118,000 40,813,000 27,614,000 13,076,000 1,871,000   10,000,000  15,277,000 539,000 338,000 1,240,000 22,017,000 33,432,000   
  operating expenses:                    
  cost of sales6,237,000 5,211,000 4,926,000 3,242,000 3,004,000 1,654,000 1,216,000 377,000             
  gross profit                    
  yoy                    
  qoq                    
  gross margin %                    
  research and development15,594,000 14,409,000 16,873,000 12,128,000 12,319,000 12,066,000 13,305,000 12,105,000 12,546,000 12,356,000 10,028,000 10,912,000 9,603,000 12,081,000 8,038,000 10,209,000 7,204,000 16,261,000 7,587,000 7,991,000 
  selling, general and administrative103,013,000 84,995,000 69,030,000 57,910,000 58,792,000 51,578,000 43,005,000 30,324,000             
  total operating expenses124,844,000 104,615,000 90,829,000 73,280,000 74,115,000 65,298,000 57,526,000 42,806,000 32,821,000 27,452,000 25,061,000 22,906,000 20,501,000 20,060,000 14,786,000 16,945,000 14,735,000 22,718,000 11,477,000 10,141,000 
  income from operations before other income-22,184,000 -26,280,000 -24,037,000 -25,162,000 -33,302,000 -37,684,000               
  other income:                    
  interest income4,229,000 3,454,000 3,647,000 4,120,000 4,130,000 3,117,000 2,978,000 2,840,000 2,226,000 2,293,000 2,127,000 1,061,000 -247,000 -316,000 12,000 8,000 7,000 9,000 10,000 4,000 
  interest expense-2,240,000 -2,213,000 -2,312,000 -2,445,000 -2,109,000 -983,000 -989,000 -858,000 -815,000 -684,000 -692,000 -633,000         
  loss on debt extinguishment    -1,944,000                
  other income-145,000 -81,000 -27,000 67,000 -59,000 605,000 -13,000 -48,000 -47,000 6,000 -50,000 -7,000 106,000 37,000 -5,000 5,000 -39,000 -34,000   
  total other income1,844,000 1,160,000 1,308,000 1,742,000 12,000 1,953,000 2,548,000 1,787,000 1,397,000 1,533,000 1,462,000 390,000 -519,000 -716,000 -349,000 -333,000 -908,000 -25,000 10,000 4,000 
  net income-20,340,000 -25,120,000 -23,113,000 -23,420,000 -33,290,000 -35,731,000 -41,902,000 -39,148,000 -31,424,000 -23,419,000 -13,599,000 -22,511,000         
  yoy-38.90% -29.70% -44.84% -40.18% 5.94% 52.57% 208.13% 73.91%             
  qoq-19.03% 8.68% -1.31% -29.65% -6.83% -14.73% 7.03% 24.58% 34.18% 72.21% -39.59%          
  net income margin %                    
  unrealized gain on marketable securities and cash equivalents-46,000 -94,000 -167,000 522,000 -113,000 -61,000 6,000 15,000 47,000 4,000           
  comprehensive loss-20,386,000 -25,214,000 -23,280,000 -22,898,000 -33,403,000 -35,792,000 -41,896,000 -39,133,000 -31,377,000 -23,415,000           
  net income per share-0.48 -0.64 -0.59 -0.61 -0.88 -1.01 -1.27 -1.28 -1.17 -0.88 -0.49 -0.84 -0.24 -0.98     1.41 -3.71 
  weighted-average shares outstanding, basic and diluted42,360,452 39,345,359 37,604,538 38,381,968 37,823,233 35,300,655 29,383,276 30,622,440   24,619,700          
  realized/unrealized loss on equity investments  -147,750                  
  change in fair value of equity warrants issued by licensee     -201,000 152,000 -36,000 18,000 -17,000 19,000 -18,000 -257,000        
  other comprehensive gain:                    
  realized/unrealized gain on equity investments    -6,000                
  other comprehensive loss:                    
  unrealized loss on equity investments     -585,000 -40,250 -111,000  -65,000 58,000 -13,000 -121,000        
  cost of license fees and collaboration revenue          400,000  522,000 33,000 -24,000 65,000 737,000 1,297,000   
  income from operations before other income and income taxes      -24,677,000 -40,935,000 -32,821,000 -24,952,000 -15,061,000 -22,906,000 -5,224,000 -19,521,000 -14,448,000 -15,705,000 7,282,000 10,714,000 -11,477,000 -10,141,000 
  benefit from income taxes                -29,000 -313,000  -1,000 
  general and administrative        20,275,000 15,096,000 14,633,000 11,994,000 10,376,000 7,946,000 6,772,000 6,671,000 6,794,000 5,160,000 3,890,000 2,150,000 
  unrealized gain on equity investments        15,000            
  weighted-average shares outstanding, basic        26,815,733 26,742,023  26,662,374 24,332,531 20,710,224       
  weighted-average shares outstanding, diluted        26,815,733 26,742,023  26,662,374 24,332,531 20,710,224       
  license fees          10,000,000  13,893,000   708,000 19,048,000 33,311,000   
  collaboration revenue            1,384,000 539,000 338,000 532,000 2,969,000 121,000   
  benefit for income taxes           5,000  -1,000 -250 341,000     
  other comprehensive income:                    
  unrealized loss on marketable securities and cash equivalents          -64,000 -10,000         
  comprehensive income          -12,125,500 -22,521,000         
  net income and comprehensive income            -5,743,000 -20,238,000 256,000 -15,697,000 6,345,000 10,376,000   
  unrealized loss on equity securities             -192,000       
  change in fair value of equity warrants             -245,000       
  net (loss) per share, basic             -0.98       
  change in fair value of equity warrant rights              -305,500 -346,000 -876,000    
  net income per share-0.48 -0.64 -0.59 -0.61 -0.88 -1.01 -1.27 -1.28 -1.17 -0.88 -0.49 -0.84 -0.24 -0.98     1.41 -3.71 
  basic              0.013 -0.76 0.31 0.51   
  diluted              0.013 -0.76 0.29 0.47   
  weighted-average shares outstanding                    
  basic               20,641,285 20,555,258 20,336,022   
  diluted               20,641,285 21,966,599 21,824,574   
  change in fair value of derivative liabilities                    
  net income and comprehensive loss                  -11,467,000 -10,138,000 
  weighted-average common shares outstanding, basic and diluted                   2,729,685 

We provide you with 20 years income statements for Tarsus Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Tarsus Pharmaceuticals stock. Explore the full financial landscape of Tarsus Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Tarsus Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.